BIOCYTOGEN-B (02315) experienced a significant surge in its stock price, soaring 8.81% during intraday trading on Wednesday. This impressive rally comes on the heels of the company's recently released strong interim results and highlighted technological advancements.
The biotech firm reported robust financial performance for the first half of 2025, with revenue reaching RMB 621 million, marking a substantial 51.3% year-on-year increase. Notably, the company successfully turned its bottom line from loss to profit, with profit attributable to shareholders amounting to RMB 47.999 million. This financial turnaround has evidently boosted investor confidence in BIOCYTOGEN-B's growth trajectory.
BIOCYTOGEN-B's success can be attributed to its dual-engine growth model, which centers on innovative animal models and antibody molecule licensing and development. The company's preclinical products and services business, focusing on innovative animal model sales, saw a 56.9% year-on-year increase in operating revenue, reaching RMB 458 million with an impressive gross margin of approximately 70%. Similarly, the antibody discovery business generated operating revenue of RMB 163 million, up 37.8% year-on-year, boasting an even higher gross margin of about 90%. These strong performances across key business segments have likely contributed to the stock's significant price appreciation.
Looking ahead, BIOCYTOGEN-B's long-term growth prospects appear promising. The company's unique platform-based innovative biotech approach, underpinned by its globally leading gene editing technology, sets it apart from traditional CROs and pharmaceutical companies. Furthermore, its RenMice series fully human antibody mouse platform, the "Thousand Mice, Ten Thousand Antibodies" program, and a global patent network have helped BIOCYTOGEN-B establish formidable technological and patent moats. As the company continues to solidify its position as a "global new drug origin," investors seem optimistic about its future potential, contributing to the stock's impressive performance.